Skip to main content

Month: September 2020

Hálfsársuppgjör Akureyrarbæjar 2020

Afkoma Akureyrarbæjar undir áætlunm.a. vegna heimsfaraldurs Covid-19Árshlutareikningur fyrir A- og B-hluta Akureyrarbæjar fyrir tímabilið 1. janúar til 30. júní 2020 var lagður fram í bæjarráði í dag. Árshlutauppgjörið er óendurskoðað en verður með könnunaráritun eftir fund bæjarstjórnar.Rekstrarniðurstaða A- og B-hluta á fyrri hluta ársins var neikvæð um 1.297,5 milljónir króna en áætlun gerði ráð fyrir að rekstrarhalli yrði 1.154,1 milljónir króna á tímabilinu. Afkoma samstæðunnar á fyrri hluta ársins er því nokkuð lakari en áætlunin.Rekstrarniðurstaða A-hluta á fyrri hluta ársins var neikvæð um 1.096,5 milljónir króna en áætlun gerði ráð fyrir að rekstrarhalli yrði 1.181,3 milljónir króna á tímabilinu. Afkoma A-hluta er því nokkru betri en áætlun gerði ráð fyrir.Tekjur samstæðunnar voru samtals 13.143 milljónir króna en áætlun gerði...

Continue reading

Chimerix to Participate in Upcoming Investor Conferences

DURHAM, N.C., Sept. 10, 2020 (GLOBE NEWSWIRE) — Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that management will participate in the following investor conferences in September:H.C. Wainwright 22nd Annual Global Investment Conference: Chimerix will present a corporate overview on Monday, September 14 at 1:00 p.m. ET and participate in investor meetings.Cantor Fitzgerald Virtual Healthcare Conference: Management will participate in investor meetings on Wednesday, September 16.A live audio webcast of the H.C. Wainwright conference presentation will be available on the Investor Relations section of Chimerix’s website at ir.chimerix.com, where it will be archived for approximately 90 days.About ChimerixChimerix...

Continue reading

Cancer Genetics Announces Participation at the 22nd Annual Rodman & Renshaw Global Investment Conference

RUTHERFORD, N.J., Sept. 10, 2020 (GLOBE NEWSWIRE) — Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today announced it will present at the 22nd Annual Rodman & Renshaw Global Investment Conference sponsored by H.C. Wainwright & Co., LLC. The conference is being held virtually from September 14-16, 2020.Event: 22nd Annual Rodman & Renshaw Global Investment ConferenceDate: September 16, 2020Time: 11:30am ETConference Details: www.rodmanevents.comCancer Genetics’ management team will provide an overview of the Company’s business and scientific advancements during the live presentation and will be available to participate in one-on-one virtual meetings with investors who are registered to attend the conference. Management will...

Continue reading

Catalyst Biosciences to Participate in Two Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Sept. 10, 2020 (GLOBE NEWSWIRE) — Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that Nassim Usman, Ph.D., president and chief executive officer and Clinton Musil, chief financial officer of Catalyst Biosciences, will participate in fireside chats at two investor conferences in September: The Morgan Stanley Global Healthcare Conference and the Cantor Virtual Global Healthcare Conference. Details for each can be found below.An archived webcast of the presentations will be available for 90 days on the Events and Presentations page under the Investors section of the Company’s website.About Catalyst BiosciencesCatalyst is a research and clinical development biopharmaceutical company focused on addressing unmet needs in rare hematologic and complement-mediated disorders. Our protease engineering...

Continue reading

Galectin Therapeutics Inc. to Present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 14, 2020

NORCROSS, Ga., Sept. 10, 2020 (GLOBE NEWSWIRE) — Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that management will present at the H.C. Wainwright 22nd Annual Virtual Global Investment Conference, on Monday, September 14, 2020, at 12:30 p.m. EDT.A live webcast of the presentation may be accessed on the conference’s website at https://wsw.com/webcast/hcw7/galt/1598408 or on the Company’s website www.galectintherapeutics.com. Management will also be available for one-on-one meetings with investors throughout the conference, which runs September 14 – 16, 2020.For additional information or to schedule a one-on-one meeting with Galectin, please contact your H.C. Wainwright representative or email ir@galectintherapeutics.com.About Galectin Therapeutics Galectin...

Continue reading

Histogen Announces Completion of Dosing Milestone in its 1b/2a Trial for Androgenic Alopecia in Men

SAN DIEGO, Sept. 10, 2020 (GLOBE NEWSWIRE) — Histogen Inc. (NASDAQ: HSTO),  a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function, today announced completion of patient dosing for the week 6 treatment timepoint in its Phase 1b/2a clinical trial of HST-001, designed to assess the safety, tolerability and indicators of efficacy of HST-001 for the treatment of androgenic alopecia in men.“We are pleased to have accomplished the second of three treatment timepoints in our HST-001 trial and we remain on track to announce top line data results in the fourth quarter of this year,” said Richard W. Pascoe, Histogen’s President and CEO.  “HST-001, if approved, could be a first-in-class product given...

Continue reading

New CLHS cameras engineered for true high-performance image capture

WATERLOO, Ontario, Sept. 10, 2020 (GLOBE NEWSWIRE) — Teledyne DALSA, a Teledyne Technologies [NYSE:TDY] company and global leader in machine vision, is pleased to announce its new Falcon4-CLHS M4480 and M4400, based on the Teledyne e2v Lince 11.2M monochrome sensors. The new Falcon4-CLHS models deliver easy-to-use, CLHS interface cameras that have been specifically engineered for industrial imaging applications requiring high-speed data transfer. These models can reach multiple thousands of frames per second in partial scan mode, and when using the sensor’s binning mode, can reach a very large pixel full well capacity of over 160Ke.“The new Teledyne e2v Lince 11.2M CMOS image sensors provide excellent performance and image quality for any machine vision applications that require true high-performance imaging,” said Manny Romero,...

Continue reading

性能卓越的新款 CLHS 相机,专为捕获优质图像而设计

加拿大滑铁卢, Sept. 10, 2020 (GLOBE NEWSWIRE) — 机器视觉技术的全球领导者,Teledyne Technologies [NYSE:TDY] 公司旗下的 Teledyne DALSA 很高兴宣布推出基于 Teledyne e2v Lince 11.2M 单色传感器的新款 Falcon4-CLHS M4480 和 M4400。新款 Falcon4-CLHS 的 CLHS 接口相机易于使用,专为需要高速数据传输的工业成像应用而设计。这些型号在部分扫描模式下每秒可拍摄几千帧图像,当使用传感器的合并模式时,可以达到超过 160Ke 的超大像素满井容量。Teledyne DALSA 高级产品经理 Manny Romero 表示:“新的 Teledyne e2v Lince 11.2M CMOS 图像传感器性能卓越,可以拍摄出色的图像,适用于所有需要真正高性能成像功能的机器视觉应用。有了这些最新的 Falcon4-CLHS 型号,我们现在的相机阵容非常强大,包括从帧数高达 609 fps 的全分辨率高速 11.2 M 相机到帧数同样达到 16 fps 之多的高分辨率 86 MP 相机的系列。”Falcon4-CLHS 利用标准布线技术(例如 CX4 和光纤 (AOC) 缆线),最大限度地提高长度和速度。Falcon4-CLHS 相机经过专门设计,可为机器视觉工业自动化、平板显示器检测、半导体检测、PCB-AOI(自动光学检测)、航空成像等应用以及需要高性能成像功能的一般机器视觉应用提供高速、可靠的结果。主要特点:11.2M 单色版本中新增了两个型号使用传感器内合并功能时可达到较大的全井容量 >160Ke部分扫描模式 (ROI) 下每秒帧数达到数千之多这一系列支持高性能的高级相机功能,外型紧凑,易于整合还有其他分辨率超过 100M 的型号全金属机身,3 年保修有关 Falcon4-CLHS 型号的更多信息,请访问网站。如需查看优质图像,请访问在线媒体包。Teledyne...

Continue reading

專為真正的高效能影像擷取所設計的全新 CLHS 相機

加拿大滑鐵盧, Sept. 10, 2020 (GLOBE NEWSWIRE) — Teledyne Technologies [NYSE:TDY] 旗下公司暨機器視覺領域全球領導者 Teledyne DALSA 很高興宣佈在 Teledyne e2v Lince 11.2M 單色感測器的基礎上,推出全新 Falcon4-CLHS M4480 和 M4400。新的 Falcon4-CLHS 型號提供易於使用的 CLHS 介面相機,此相機經過特定設計,適用於需要高速資料傳輸的工業造影應用。這些型號在局部掃描模式下,每秒可達數千個畫面,使用感測器的合併模式時,則可達非常大的像素,最大容量超過 160Ke。Teledyne DALSA 資深產品經理 Manny Romero 表示:「新的 Teledyne e2v Lince 11.2M CMOS 影像感測器提供極佳的效能和影像品質,適用於任何需要真正高效能影像處理的機器視覺應用。加入了這些最新的 Falcon4-CLHS 型號後,我們現在很高興能提供各種相機,涵蓋範圍從完整解析度下的畫面播放速率高達 609 fps 的高速 11.2 M 相機,到畫面播放率速率高達 16 fps 的高解析度 86 MP 相機。」Falcon4-CLHS 運用了標準佈線技術,例如 CX4 和光纖 (AOC) 纜線,以最大化長度和速度。Falcon4-CLHS 相機的設計,可為各種應用提供高速、可靠的結果,例如機器視覺工業自動化、平面顯示器檢查、半導體檢查、PCB-AOI (自動化光學檢查)、空中影像處理和需要真正高效能影像處理的一般機器視覺應用。主要功能:以 11.2M 單色視覺提供兩個新型號使用感測器內合併時最大容量 >160Ke局部掃描模式 (ROI) 下每秒數千個畫面系列產品以便於整合的精巧外形,支援進階高效能相機功能其他型號計畫使用超過 100M 的解析度全金屬機身,含 3 年保固如需更多關於 Falcon4-CLHS...

Continue reading

真の高性能イメージキャプチャのために開発された新しいCLHSカメラ

カナダ、ウォータールー, Sept. 10, 2020 (GLOBE NEWSWIRE) — Teledyne Technologies(NYSE: TDY)の傘下で、マシンビジョンテクノロジーの分野において世界屈指の企業であるTeledyne DALSAは、Teledyne e2v Lince 11.2Mモノクロカメラをベースにした新しいFalcon4-CLHS M4480およびM4400を発表しました。新しいFalcon4-CLHSモデルは、高速データ転送を必要とする産業用画像処理向けに特別に設計された、使いやすいCLHSインターフェースカメラを搭載しています。このモデルは、パーシャルスキャンモードで数千FPS、センサーのビニングモード使用時には、160Keを超える極めて大きな飽和容量ピクセルを誇ります。「新しいTeledyne e2v Lince 11.2M CMOSイメージセンサーは、真の高性能画像処理を必要とするマシンビジョン用途向けに優れた性能と画質を提供します」と語るのは、Teledyne DALSAでシニアプロダクトマネージャーを務めるManny Romeroです。「最新のFalcon4-CLHSモデルを追加することにより、最大解像度で最高フレームレート609 FPSの高速11.2 Mカメラから、最高フレームレート16FPSの高解像度86 MPカメラまで、バリエーションに富んだカメラを取り揃えられたことを喜ばしく思います。Falcon4-CLHSは、CX4や光ファイバー(AOC)ケーブルなどの標準配線テクノロジーを活用し、長さと速度を最大限に発揮します。Falcon4-CLHSカメラは、マシンビジョンのインダストリアルオートメーション、フラットパネルディスプレイ検査、半導体検査、PCB-AOI(自動光学検査)、航空画像、真の高性能画像処理を必要とする一般マシンビジョンなどの用途に信頼できる結果を高速で提供するために開発されました。主な特徴:2つの新しいモデルを11.2Mモノクロバージョンで提供センサー内のビニングモード使用時は飽和容量が160Keを超えるパーシャルスキャンモード(ROI)で数千FPSシステムに組み込みやすいコンパクトな形状で最先端の高性能カメラ機能をサポート100Mを超える解像度のモデルも追加予定フルメタルボディ(3年間保証付き)Falcon4-CLHSモデルの詳細については、ウェブサイトをご覧ください。高品質イメージについては、当社のオンラインメディアキットをご覧ください。Teledyne...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.